• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of April 29


The Center for Biosimilars® recaps the top news for the week of April 29, 2019.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 29.

Number 5: The market for orphan drugs is set to grow over the next 4 years, a pharmaceutical report says.

Number 4: Researchers report that patients with psoriasis who switched between 2 different infliximab biosimilars did not have an increase in Psoriasis Area and Severity Index scores or increased adverse events.

Number 3: The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Juta Pharma’s pegfilgrastim biosimilar.

Number 2: Sandoz has entered into a partnership with Taiwan-based EirGenix for a proposed trastuzumab biosimilar referencing Herceptin.

Number 1: Last week, the FDA approved Samsung Bioepis’ etanercept biosimilar referencing Enbrel.

Finally, last week, our e-newsletter asked whether you think that Novartis’ novel eye drug could beat out future biosimilars of aflibercept.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.